Physician profile
Lisa M Bodon
NPI 1063619013
$4,213.79
in general payments reported to CMS, 2019-2025
32 companies · $306 in 2025
The $306 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $396 · 2020: $486 · 2021: $691 · 2022: $683 · 2023: $894 · 2024: $758 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,957.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $718.31 | 2019-2023 | Orilissa, Lo Loestrin Fe |
| Therapeuticsmd, INC. | $524.52 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $367.38 | 2023-2025 | |
| Hologic Sales and Service, LLC | $340.24 | 2021-2024 | Novasure, Thinprep 2000 Processor, Aptima |
| Medtronic USA, INC. | $236.84 | 2019-2020 | |
| Pfizer INC. | $204.04 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $186.69 | 2023-2025 | Myfembree |
| Antares Pharma, INC. | $163.89 | 2024-2025 | Xyosted |
| Axonics, INC. | $154.09 | 2022 | |
| Medtronic, INC. | $145.09 | 2023 | Ligasure |
| Aspira Women'S Health INC | $142.98 | 2021-2023 | Ova1 |
| Novo Nordisk INC | $122.18 | 2023 | Wegovy |
| Evofem Biosciences, INC. | $95.85 | 2021-2022 | |
| Abbott Laboratories | $73.18 | 2024 | Proclaim |
| Lilly USA, LLC | $67.66 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $67.65 | 2020-2022 | |
| Shield Therapeutics INC | $65.83 | 2024 | |
| Boston Scientific Corporation | $62.32 | 2021-2025 | Wavewriter Alpha Prime 16 |
| Amag Pharmaceuticals, INC. | $53.55 | 2019-2020 | |
| Agile Therapeutics, INC. | $52.73 | 2021-2022 | |
| Myovant Sciences INC. | $51.50 | 2022 | |
| Astellas Pharma US INC | $50.43 | 2023-2025 | Veozah |
| Amgen INC. | $48.58 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $45.07 | 2021 | |
| Allergan, INC. | $32.88 | 2019-2020 | |
| Coloplast Corp | $22.91 | 2019 | |
| Hollister Incorporated | $22.61 | 2021 | |
| 180 Medical, INC. | $21.95 | 2020 | |
| Idorsia Pharmaceuticals US INC | $20.78 | 2023 | Quviviq |
| Exact Sciences Corporation | $20.78 | 2025 | Cologuard Collection Kit |
| Halozyme INC | $18.76 | 2023 | |
| Avion Pharmaceuticals | $12.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Bodon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.